Related Experiment Videos

Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation

Miranda Thomas1, Richard Laura, Karin Hepner

  • 1International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.

Oncogene
|July 26, 2002
PubMed

Insights

High-risk human papillomavirus (HPV) E6 proteins degrade MAGI-2 and MAGI-3 proteins. Targeting a specific PDZ domain could inhibit this interaction, offering a potential therapeutic strategy against HPV.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • High-risk human papillomavirus (HPV) E6 oncoproteins are known to target PDZ domain-containing proteins, such as hDlg and MAGI-1, for proteasomal degradation.
  • This degradation mechanism is implicated in viral oncogenesis and tumor progression.

Purpose of the Study:

  • To investigate whether high-risk HPV E6 proteins also target MAGI-2 and MAGI-3 proteins for degradation.
  • To determine the specificity of the interaction between HPV E6 and MAGI proteins within the PDZ domain.
  • To explore the potential for therapeutic intervention by inhibiting E6-MAGI protein interactions.

Main Methods:

  • Co-immunoprecipitation assays to detect protein-protein interactions.
  • Western blotting to assess protein levels and degradation.
  • Expression of full-length MAGI proteins and isolated PDZ domains in cell culture systems.

Main Results:

  • High-risk HPV E6 proteins were shown to induce the degradation of MAGI-2 and MAGI-3 proteins.
  • The interaction between HPV E6 and MAGI proteins was found to be specific to a single PDZ domain.
  • Co-expression of this specific PDZ domain conferred protection to full-length MAGI proteins against E6-mediated degradation.

Conclusions:

  • Oncogenic HPV E6 proteins target MAGI-2 and MAGI-3 for proteasomal degradation, expanding the known repertoire of E6 targets.
  • The interaction is mediated by a specific PDZ domain, highlighting a potential Achilles' heel for therapeutic targeting.
  • These findings provide a strong rationale for designing compounds that inhibit the E6-PDZ domain interaction to counteract the effects of oncogenic HPV.

Related Concept Videos